Compare Cognizant Technology Solutions Corp (CTSH) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cognizant Technology Solutions Corp vs BIO-TECHNE Corp — how do they compare? Cognizant Technology Solutions Corp trades at $58.38 (market cap $26.27B), while BIO-TECHNE Corp trades at $72.16 (market cap $11.24B). The key difference: Cognizant Technology Solutions Corp is far larger — about 2.3× BIO-TECHNE Corp's market cap, and Cognizant Technology Solutions Corp pays the higher dividend (2.26%). Which is the better fit depends on your goals.
| CTSH | TECH | |
|---|---|---|
Market Cap | $26.27B | $11.24B |
Sector | Technology | Health |
52-Week High | $86.70 | $72.29 |
52-Week Low | $38.73 | $43.31 |
Enterprise Value | $27.31B | $11.32B |
Dividend Yield | 2.26% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTSH trades at $57.67, up 1.37% with a bullish technical signal. Recent Q2 2026 earnings missed EPS estimates at $1.37 versus $1.38 expected, though revenues beat. The company maintains solid fundamentals with a P/E of 12.37 and ROE of 14.92%, supported by strong cash flow from operations of $2.88B in 2025. AI initiatives, including the new EMEA AI Unit, highlight growth efforts amid cautious client spending.
Outlook is mixed: valuation appears attractive with upside to the $59.92 consensus target, but risks include macroeconomic pressures on IT spending and competitive disruption from AI. Earnings consistency and AI adoption execution are critical for sustained gains.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cognizant Technology Solutions Corp
Cognizant is a global IT services provider, offering consulting and outsourcing services to some of the world's largest enterprises spanning the financial services, media and communications, healthcare, natural resources, and consumer products industries. Cognizant employs nearly 300,000 people globally, roughly 70% of whom are in India, although the company's headquarters are in Teaneck, New Jersey.
Read more on CTSH →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
